Affini-T Therapeutics Alternatives & Competitors
12 companies similar to Affini-T Therapeutics — Right Targets. Right Cells. Right Place. Unlocking the power of T cells against...
Companies similar to Affini-T Therapeutics
Minerva Biotechnologies
We see the future first
Waltham, United States
CERo Therapeutics, Inc.
Tumor Cell Clearance Reimagined.
South San Francisco, Unit...
Zelluna Immunotherapy
Developing allogeneic TCR-NK therapies for solid tumors
Oslo, Norway
Strand Therapeutics
Where synthetic biology meets RNA therapeutics
Boston, United States
Rival Readout
Competing with Affini-T Therapeutics? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Refuge Biotechnologies
DESIGNING INTELLIGENT CELL THERAPIES TO FIGHT CANCER
Menlo Park, United States
Alaunos Therapeutics
Attacking solid tumors with TCRs
Houston, United States
Poseida Therapeutics, Inc.
A Member of the Roche Group
San Diego, United States
Crossbow Therapeutics, Inc
Established antibody engineering to target the untapped universe of intracellular cancer t...
Cambridge, United States
OXFORD VACMEDIX UK LIMITED
Developing therapeutic cancer vaccines using ROP technology
Oxford, United Kingdom
Cybrexa Therapeutics
Changing the paradigm for cancer treatment through the development of antigen-independent...
New Haven, United States
PMV Pharmaceuticals, Inc.
Harnessing the power of p53 to treat cancer
Princeton, United States
CatalYm GmbH
Developing innovative immunotherapies to transform cancer patients’ lives by engaging thei...
Germany
About Affini-T Therapeutics
Affini-T Therapeutics, founded in 2021, is a pioneering clinical-stage precision immunotherapy company headquartered in the United States. The company focuses on targeting oncogenic driver mutations, with an initial focus on KRAS, to create potentially curative therapies for patients with solid tumors. Their slogan, "R...
Developing specific TCR-based immunotherapies, Targeting oncogenic driver mutations, Conducting clinical trials and preclinical research
Cancer patients, Healthcare providers specializing in oncology, Research institutions, Pharmaceutical companies
Precision Immunotherapy, Oncogenic Driver Mutations, KRAS, Solid Tumor Therapies, T Cell Receptor (TCR) Therapy, Adoptive Cellular Therapy, Bispecific T Cell Engagers, Synthetic Biology, Gene Editing, Cancer Therapeutics, High-Affinity T Cell Receptors, Tumor Eradication, Proprietary Platforms, Cell Engineering, Biotechnology Innovation
B2B, B2D
Licensing, Performance Based, Project Based
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Affini-T Therapeutics: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Affini-T Therapeutics on 9 Jun 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
